VAC Coverage for Psychedelic-Assisted Therapy (Canada 2026)

For Canadian veterans with service-related conditions, the most important thing to understand about Veterans Affairs Canada and psychedelic medicine is a single distinction. VAC covers ketamine as a medication for some service-related conditions. VAC does not fund psychedelic-assisted psychotherapy, including ketamine-assisted psychotherapy, psilocybin-assisted therapy, or MDMA-assisted therapy. This article explains that line clearly, so you can plan with the real picture rather than a hopeful one.

Medically reviewed by Jacque Lovely, RN, MN, MBA, PMP, Reg #74334 on 2026-05-27.

Key takeaways

• VAC covers ketamine as a drug, not as a therapy program. Per its December 2024 position, VAC will consider funding ketamine (as an infusion, oral ketamine, or Spravato (esketamine) nasal spray) for treatment-resistant depression or depression co-existing with PTSD, and ketamine forms for chronic pain, when prescribed by a treating psychiatrist [VAC 2024]. Specific eligibility criteria and coverage amounts vary; confirm directly with VAC.
• VAC does NOT fund psychedelic-assisted psychotherapy. This includes ketamine-assisted psychotherapy (KAP), psilocybin-assisted therapy, and MDMA-assisted therapy. VAC's stated reason is that delivering psychotherapy to someone in a drug-induced psychedelic state remains an emerging treatment without sufficient evidence [VAC 2024].
• The medication and the therapy are funded separately. VAC may pay for your ketamine prescription through a prescriber, while the assisted-psychotherapy component is generally out-of-pocket.
• ATMA CENA's programs are psychotherapy-inclusive. ATMA CENA's ketamine programs combine the medication with structured therapy, which likely falls in the not-funded category. VAC may cover your ketamine drug cost via your prescriber, but not the assisted-therapy program.
• Eligibility requires service-connection. VAC covers conditions connected to service in the Canadian Armed Forces, RCMP, or other eligible service. Civilian conditions without service-connection are not VAC-eligible.
• Policy can change. VAC's position is dated; confirm current coverage with VAC and your prescriber before making plans.

If you are a Canadian veteran or RCMP member with a service-related condition researching this, you can book a free information call to talk through what VAC realistically covers and where the gaps are.

Does VAC cover psychedelic-assisted therapy?

The honest answer requires separating two things that are easy to blur together: the drug, and the therapy built around the drug. VAC covers ketamine as a pharmacological medication for certain service-related conditions, when a treating psychiatrist prescribes it. VAC does not fund psychedelic-assisted psychotherapy, the structured therapy protocol in which the drug-induced state is an intentional part of the treatment. Per VAC's December 2024 position, that exclusion applies to ketamine-assisted psychotherapy, psilocybin-assisted therapy, and MDMA-assisted therapy alike [VAC 2024]. The reason VAC gives is that providing psychotherapy to someone in a drug-induced psychedelic state remains an emerging therapy without enough scientific evidence to meet its standard for reimbursement. So a veteran might have a ketamine prescription covered by VAC while paying out-of-pocket for the assisted-therapy program around it. This distinction is the whole point of this page, and it is one that earlier guidance circulating online often got wrong.

Pro tip: When you talk to VAC or a clinic, ask the question precisely. "Will VAC cover the ketamine medication my psychiatrist prescribes?" is a different question from "Will VAC cover the ketamine-assisted therapy program?" The first may be yes; the second is currently no.

What VAC covers, and what it does not

The clearest way to hold this is a single table. The left column is what VAC will consider funding as a medication; the right column is what it does not fund as an assisted-psychotherapy program.

What you are asking VAC to fund	VAC position (per Dec 2024)
Ketamine as a medication (infusion, oral, Spravato nasal spray) for service-related treatment-resistant depression, or depression co-existing with PTSD, prescribed by a treating psychiatrist	Considered for funding, case-by-case [VAC 2024]
Ketamine forms (infusion, oral, compounded cream/topical) for service-related chronic pain	Considered for funding, case-by-case [VAC 2024]
Ketamine-assisted psychotherapy (KAP), the medication delivered inside a structured therapy protocol	Not funded [VAC 2024]
Psilocybin-assisted therapy	Not funded [VAC 2024]
MDMA-assisted therapy	Not funded [VAC 2024]

The pattern is consistent: VAC funds the ketamine drug when it is prescribed and administered as a medication, and it does not fund any of the assisted-psychotherapy protocols, regardless of substance. Psilocybin and MDMA have no funded pathway at VAC at all, because there is no approved-medication route for them in Canada; legal access runs only through a Health Canada approval granted on a case-by-case basis and initiated by a physician, and VAC does not reimburse the therapy. Specific eligibility criteria and coverage amounts vary by case; confirm directly with VAC.

Why VAC draws the line where it does

VAC's published rationale is evidentiary. Ketamine is approved by Health Canada as an anaesthetic and has an established pharmacological evidence base; VAC treats it as a covered medication on that footing. The assisted-psychotherapy model, where the altered state is a deliberate part of the therapeutic work, is what VAC describes as still emerging. Because the assisted-therapy protocol is the unit VAC declines to fund, the same answer applies whether the substance is ketamine, psilocybin, or MDMA [VAC 2024]. Understanding this helps you avoid a common and costly assumption: that getting the ketamine drug covered means the whole program is covered. It does not.

How this affects ATMA CENA's programs specifically

This is the part veterans most need stated plainly. ATMA CENA's ketamine programs are psychotherapy-inclusive. They combine the medication with structured preparation, a supervised dosing session, and integration work, which is the definition of ketamine-assisted psychotherapy. Under VAC's current position, that program likely falls into the not-funded category, even though the ketamine medication inside it may be coverable when prescribed by your psychiatrist as a medication [VAC 2024].

In practice, that means a realistic plan often has two separate funding channels:

• The medication. If a treating psychiatrist prescribes ketamine for your service-related condition, VAC may cover the drug cost through the prescriber pathway, subject to its case-by-case review.
• The therapy program. The preparation, the supervised dosing session, and the integration work that make up an assisted-therapy program are generally out-of-pocket for veterans today.

We would rather you know this before you start than discover it on an invoice. If a coverage gap is the deciding factor for you, the information call is the place to talk through what your specific situation makes possible.

Who is VAC-eligible?

VAC health benefits depend on service-connection. VAC provides coverage to Canadian Armed Forces veterans with eligible service, Royal Canadian Mounted Police members with eligible service, and certain dependants and survivors of eligible service members. The condition being treated must be connected to that service. Civilian conditions without a service-connection are not VAC-eligible; those patients pursue private insurance, provincial drug plans, or other pathways instead. Actively serving CAF members are generally covered through Canadian Forces Health Services rather than VAC, and may transition to VAC coverage after release. For the official scope of what VAC covers, see Veterans Affairs Canada Mental Health Benefits. The exact line items, dose limits, and prior-authorization steps in VAC's benefit grid vary and are not published in detail, so confirm the specifics for your situation directly with VAC and your prescriber.

What the ketamine-coverage numbers tell us

You may have seen figures reported for how many veterans use VAC ketamine coverage in a given year. Two things are worth reading carefully about any such number. First, these figures refer to ketamine reimbursed as a medication, consistent with the distinction this whole article is built on; they are not evidence that VAC funds ketamine-assisted therapy programs. Second, any published figure is a single fiscal-year snapshot from a past reporting period, so it should be treated as historical rather than current, and the specific counts and amounts vary year to year. We mention this only to show that a real, if narrow, medication-coverage pathway exists, not to suggest a specific dollar amount you should expect. Confirm current coverage amounts directly with VAC.

If VAC will not fund the therapy, what are your options?

Knowing the gap lets you plan around it honestly. A few realistic paths:

• Use the medication coverage you can get, and plan for the therapy as out-of-pocket. If your psychiatrist prescribes ketamine and VAC covers the drug, that reduces, but does not eliminate, your cost.
• Check provincial workers' compensation if you have post-service occupational exposure. Some veterans move into work such as corrections, paramedicine, or wildland firefighting. Provincial workers' compensation boards can have their own coverage rules for service-related and work-related PTSD, distinct from VAC.
• Understand the MDMA-AT picture before counting on it. For veterans specifically interested in MDMA-assisted therapy for PTSD, it is important to understand the access route and the out-of-pocket reality. VAC does not fund it.
• Keep your existing therapist in the picture. Many veterans already have a trusted, often VAC-funded, therapist. Through our CoCare program, ATMA CENA can partner with your therapist if they have the appropriate training and build a service agreement with us, which can also affect how the pieces are billed.

For the full landscape of Canadian coverage pathways across insurers and provinces, see the insurance coverage hub.

How ATMA CENA supports VAC-eligible veterans

ATMA CENA does not control VAC decisions, and we will not tell you a program is covered when it is not. What ATMA CENA can do is help you see the real shape of your options. The prescribing decision, and any VAC medication claim, sits with your treating physician, often a VAC-affiliated psychiatrist experienced in these treatments. ATMA CENA supports the preparation, the medically supervised dosing session, and the integration work that surround a course of treatment. For veterans who already have a trusted therapist who understands the service context, our CoCare program can partner with that therapist if they have the appropriate training and build a service agreement with us, while ATMA CENA provides the dosing-specific clinical frame. The information call screens for service-connection, walks through which pieces VAC may cover as a medication versus which are out-of-pocket as therapy, and orients you to alternatives if the funding gap changes your plan.

Frequently asked questions

Does VAC cover psychedelic-assisted therapy?

Not as a therapy program. Per its December 2024 position, VAC does not fund psychedelic-assisted psychotherapy, including ketamine-assisted psychotherapy, psilocybin-assisted therapy, or MDMA-assisted therapy. VAC will, however, consider funding ketamine as a medication (infusion, oral, or Spravato nasal spray) for service-related treatment-resistant depression or chronic pain, when prescribed by a treating psychiatrist. The drug and the therapy are funded separately, and the therapy component is currently not funded. Confirm current policy with VAC before making plans.

Will VAC pay for my ketamine if I do a ketamine-assisted therapy program at ATMA CENA?

VAC may cover the ketamine medication itself if a treating psychiatrist prescribes it for your service-related condition, subject to VAC's case-by-case review. It does not follow that VAC covers the assisted-therapy program. ATMA CENA's ketamine programs are psychotherapy-inclusive, which likely falls into VAC's not-funded category. So the realistic picture is often a covered medication plus an out-of-pocket therapy program.

Does VAC cover psilocybin or MDMA therapy?

No. VAC does not fund psilocybin-assisted therapy or MDMA-assisted therapy. Neither substance has an approved-medication route in Canada; legal access requires Health Canada approval on a case-by-case basis, initiated by a physician, and VAC does not reimburse the therapy. Veterans accessing these therapies this way currently pay out-of-pocket.

Why doesn't VAC fund the assisted-therapy part?

VAC's stated reason is evidentiary: providing psychotherapy to someone in a drug-induced psychedelic state remains an emerging therapy without sufficient scientific evidence to meet VAC's standard for reimbursement. Ketamine as a pharmacological medication has an established footing and is treated differently. Because VAC declines to fund the assisted-psychotherapy protocol itself, the same answer applies whether the substance is ketamine, psilocybin, or MDMA.

Does VAC require my condition to be service-related?

Yes. VAC covers conditions connected to service in the Canadian Armed Forces, RCMP, or other eligible service. A condition without a service-connection is not VAC-eligible, and those patients pursue private insurance, provincial drug plans, or other pathways. The service-connection determination is part of VAC's process and is separate from any clinical decision about ketamine.

Are RCMP members eligible?

Yes. RCMP members with eligible service are covered under VAC health benefits, on the same service-connection basis as Canadian Armed Forces veterans. The same drug-versus-therapy distinction applies: VAC may consider funding ketamine as a medication, but does not fund psychedelic-assisted psychotherapy.

What about actively serving CAF members?

Actively serving Canadian Armed Forces members are generally covered through Canadian Forces Health Services rather than VAC. Coverage frameworks during active service differ, and some members transition to VAC coverage after release. If you are serving, confirm your current coverage through your own health services rather than assuming VAC rules apply yet.

What if VAC denies my claim?

VAC has review and appeal processes, and additional clinical documentation can sometimes support a reconsideration of a medication claim. Keep in mind that the assisted-therapy program is currently outside VAC's funded scope, so an appeal is more likely to be relevant to the medication coverage than to the therapy program. Confirm the current appeal steps with VAC directly. The information call can help orient you to alternatives if a denial changes your plan.

Can my existing therapist stay involved?

Often yes, through the CoCare program. Many veterans have a trusted therapist, sometimes one funded through other VAC mental-health benefits, who understands the service context. Through CoCare, ATMA CENA can partner with your therapist if they have the appropriate training and build a service agreement with us, while providing the medical and dosing-specific frame. This can also affect how the pieces are billed, since the therapist's hours may be handled separately from the medication and dosing infrastructure.

Compliance and access

Ketamine is approved by Health Canada as an anaesthetic. Use for depression, anxiety, PTSD, and other mental-health indications is off-label, regulated by provincial medical regulators (for example, CPSA in Alberta, CPSO in Ontario, CPSM in Manitoba). Esketamine (Spravato) is Health Canada-approved for treatment-resistant depression in adults aged 18 to 64, in combination with an SSRI or SNRI, and requires in-clinic dosing supervision; initiation in patients aged 65 and over is not recommended. Psilocybin and MDMA are restricted drugs under Canada's Controlled Drugs and Substances Act. Legal patient access to psilocybin- or MDMA-assisted therapy requires Health Canada approval on a case-by-case basis, initiated by a physician, and is not guaranteed. Such approvals have primarily been granted for adults with treatment-resistant major depressive disorder or distress associated with a life-threatening illness (for psilocybin) and for adults with PTSD (for MDMA).

This article is educational and is not financial, tax, insurance, or medical advice. Coverage decisions belong to Veterans Affairs Canada, and clinical decisions belong with a qualified prescribing physician who can assess your individual situation. Nothing here should be read as a guarantee of coverage, access, or benefit. VAC policy can change; confirm current coverage with VAC and your prescriber before making plans.

About the author

Reverdi Darda, RN, BScN, Reg #61707 | CEO & Founder, ATMA CENA

Reverdi Darda, RN is CEO & Founder of ATMA CENA and a Registered Nurse with over three decades of experience in healthcare operations, community engagement, policy development, and strategic planning. A recognized leader in mental health access, Reverdi has dedicated her career to advancing evidence-based treatment models and advocating for policy change that prioritizes effective care. She founded ATMA CENA to expand practitioner and public access to psychedelic-assisted therapy across Canada.

Reviewed by Jacque Lovely, RN, MN, MBA, PMP, Reg #74334 on 2026-05-27.

Sources

1. Veterans Affairs Canada (2024). Mental Health Benefits and coverage. https://www.veterans.gc.ca/en/financial-programs-and-services/medical-costs/coverage-services-prescriptions-and-devices/mental-health-benefits
2. Veterans Affairs Canada (December 2024). Mental Health Treatments (ministerial briefing). https://public.cdn.cloud.veterans.gc.ca/pdf/about-vac/who-we-are/department-officials/minister/briefing/dec2-2024/16-mental-health-treatments-en.pdf
3. Health Canada. Notice on requests involving psychedelic-assisted psychotherapy. https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/requests-special-access-program-psychedelic-assisted-psychotherapy.html
4. Swainson J, et al. (2023). Use of ketamine for treatment-resistant depression: updated review of literature and practical applications to a community ketamine program in Edmonton, Alberta, Canada. Frontiers in Psychiatry, 14:1283733. https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2023.1283733/full
5. Mitchell JM, et al. (2021). MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study (MAPP1). Nature Medicine. https://pubmed.ncbi.nlm.nih.gov/33972795/
6. Mithoefer MC, et al. (2018). MDMA-assisted psychotherapy for PTSD in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 trial. Lancet Psychiatry. https://pubmed.ncbi.nlm.nih.gov/29728331/
7. ATMA CENA. Information call. https://atmacena.com/information-call/
8. ATMA CENA. CoCare: working with your existing therapist. https://atmacena.com/cocare/

Related articles in this cluster

• Insurance Coverage for Psychedelic-Assisted Therapy in Canada (Hub) (parent hub)
• CoCare: How ATMA CENA Works With Your Existing Therapist (keeping your therapist primary)

---

Last updated: 2026-05-27. This article is reviewed every 3 months because it covers regulatory and coverage information that can change.